On October 3, 2024, the Food Tech Summit & Expo in Mexico concluded successfully. BioGrowing captured significant attention with its innovative achievements and forward-looking academic exchanges in the field of probiotics, attracting numerous industry clients and facilitating multiple cooperation intentions.
In recent years, probiotics have gradually gained popularity in South America. Apart from traditional probiotics, postbiotics and Weizmannia coagulans have gradually gained popularity in the market due to their excellent thermal stability. BioGrowing, leveraging its top-notch R&D capabilities and market insights, is actively expanding its presence in the South American market, showcasing strong growth potential.
At this exhibition, BioGrowing showcased its Flora-Focus® probiotic product range, fermentation products, and ODM/DCMO solutions, covering various functional areas such as gut health, immunity, oral health, and women’s health, highlighting the company’s capability and innovation in providing comprehensive health product solutions to clients.
Among them, BioGrowing’s independently developed Weizmannia coagulans BC-G44 showcased in multiple dosage forms, attracting considerable attention. BC-G44 is a strain developed by BioGrowing itself, derived from naturally fermented peaches, and received GRAS certification in 2024, offering high stability and long-lasting activity, making them highly popular in the market.
Meanwhile, the postbiotics brought by BioGrowing, including Lacticaseibacillus paracasei LPc-G110, Lacticaseibacillus rhamnosus JL1, Lactiplantibacillus plantarum J26, Lactiplantibacillus plantarum ZJUFN1, and Lactiplantibacillus plantarum Lp-G18, have also garnered great interest from customers due to their pure source, easy storage, strong scientific evidence, and wide application.
During the event, Dr. Hongwei Wang, CTO of the BioGrowing, delivered a public speech titled “Why We Should Live with Probiotics?”, explaining the importance of probiotics at various stages of life in a clear and accessible manner. His focus on probiotics in oral health, combating H-pylori, and women’s health sparked lively discussions among the audience.
The proprietary Lacticaseibacillus paracasei LPc-G110 developed by BioGrowing has been proven effective in inhibiting inflammation, regulating the oral microbiome, and improving clinical indicators of gingivitis. This strain demonstrates efficacy even in its inactivated state (postbiotics), providing a new solution for oral health.
Meanwhile, Lactiplantibacillus plantarum Lp-G18 has showcased exceptional results in combating Helicobacter pylori. Studies show that this strain significantly increases the eradication rate of Helicobacter pylori in individuals under 45, while reducing adverse reactions associated with traditional triple therapy. As BioGrowing’s star strain, Lp-G18 has won multiple international awards for its outstanding performance.
The remarkable efficacy of probiotics in women’s intimate health is receiving increasing attention. This time, BioGrowing introduced the newly launched Lactobacillus crispatus Lc-G22, which can maintain an acidic vaginal environment, effectively eliminate pathogenic bacteria, and promote overall women’s health, catering to the intimate health needs of modern women.
This exhibition not only showcased the research strength and brand influence of BioGrowing but also laid a solid foundation for its further development in the global probiotics market. In the future, BioGrowing will continue to increase its investment in research and development, creating more high-quality products to contribute to global health initiatives.
Media Contact
Company Name: BIOGROWING CO.,LTD.
Contact Person: Echo Sun
Email: Send Email
Country: China
Website: www.biogrowing.com